102 related articles for article (PubMed ID: 19631381)
1. Translating genetic questions into clinical answers in acute myeloid leukemia.
Vora S; Ellis N; Onel K
Leuk Res; 2009 Nov; 33(11):1448-9. PubMed ID: 19631381
[No Abstract] [Full Text] [Related]
2. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
[TBL] [Abstract][Full Text] [Related]
3. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
5. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
6. MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.
El-Danasouri NM; Ragab SH; Rasheed MA; Ali El Saadany Z; Abd El-Fattah SN
Ann Clin Lab Sci; 2014; 44(4):449-54. PubMed ID: 25361931
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
8. Association of Mouse Double Minute 2 -309T>G Polymorphism with Acute Myeloid Leukemia in an Iranian Population: A Case- Control Study.
Soleymannejad M; Sheikhha MH; Neamatzadeh H
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3037-3041. PubMed ID: 31653152
[TBL] [Abstract][Full Text] [Related]
9. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
Thompson T; Andreeff M; Studzinski GP; Vassilev LT
Mol Cancer Ther; 2010 May; 9(5):1158-68. PubMed ID: 20406950
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
[TBL] [Abstract][Full Text] [Related]
11. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
12. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Phillips CL; Gerbing R; Alonzo T; Perentesis JP; Harley IT; Meshinchi S; Bhatla D; Radloff G; Davies SM
Pediatr Blood Cancer; 2010 Aug; 55(2):248-53. PubMed ID: 20582981
[TBL] [Abstract][Full Text] [Related]
13. [Study on MDM2 and p53 gene proteins expression on acute leukemic cells and its correlation with chemotherapeutic efficacy].
Lin M; Liu Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):350-2. PubMed ID: 11189516
[TBL] [Abstract][Full Text] [Related]
14. Genome-scale functional analysis of the human genes modulating p53 activity by regulating MDM2 expression in a p53-independent manner.
Kim DM; Choi SH; Yeom YI; Min SH; Kim IC
Biochem Biophys Res Commun; 2016 Sep; 478(2):976-81. PubMed ID: 27524244
[TBL] [Abstract][Full Text] [Related]
15. Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia.
Jaako P; Ugale A; Wahlestedt M; Velasco-Hernandez T; Cammenga J; Lindström MS; Bryder D
Leukemia; 2017 Jan; 31(1):213-221. PubMed ID: 27256803
[TBL] [Abstract][Full Text] [Related]
16. [Expression of MDM2 gene in acute leukemia].
Chao H; Wang J; Wang L
Zhonghua Yi Xue Za Zhi; 1995 Nov; 75(11):686-8, 711. PubMed ID: 8697092
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.
Lucas DM; Byrd JC
J Clin Oncol; 2008 May; 26(14):2244-5. PubMed ID: 18467712
[No Abstract] [Full Text] [Related]
18. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
20. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
Quintás-Cardama A; Hu C; Qutub A; Qiu YH; Zhang X; Post SM; Zhang N; Coombes K; Kornblau SM
Leukemia; 2017 Jun; 31(6):1296-1305. PubMed ID: 27885271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
